CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

6 Months Ended

Jun. 30, 2025

CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

NOTE 16 – CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

A condensed consolidating balance sheet of the Company as of June 30, 2025 follows:

	Yubo International Biotech Limited (Parent Company)			Platinum (Cayman Island) and Platinum HK (Cayman Island)			Yubo Global			Yubo Chengdu (WFOE)		Yubo Beijing (VIE Subsidiaries)			Elimination			Consolidated
ASSETS
Total Current Assets	$	—		$	359		$	77,189		$	—	$	583,747		$	(2,193	)	$	659,102
Investment in subsidiaries and variable interest entity (VIE)		(2,181,987	)		930,000			—			—		—			1,251,987			—
Intercompany receivables		—			—			436,661			—		646,873			(1,083,534	)		—
Other assets		—			—			21,531			—		866,105			(495,171	)		392,465
Total Assets	$	(2,181,987	)	$	930,359			535,381			—		2,096,725			(328,911	)		1,051,567
LIABILITIES AND SHAREHOLDERS' EQUITY
Total current liabilities	$	—		$	150,000		$	77,854		$	—	$	4,797,616		$	—		$	5,025,470
Intercompany payables		—			—			43,969			—		1,039,565			(1,083,534	)		—
Other liabilities		—			—			—			—		7,812			—			7,812
Total Liabilities		—			150,000			121,823			—		5,844,993			(1,083,534	)		5,033,282
Shareholders' Deficit:
Capital stock and additional paid in capital		—			1,569,229			835,513			—		2,163,147			(1,458,586	)		3,109,303
Accumulated deficit		(2,181,987	)		(788,870	)		(421,955	)		—		(5,911,415	)		1,959,667			(7,344,560	)
Accumulated other comprehensive income (loss)		—			—			—			—					235,013			235,013
Non—controlling interests		—			—			—			—		—			18,529			18,529
Total Deficit		(2,181,987	)		780,359			413,558			—		(3,748,268	)		756,817			(3,981,715	)
Total Liabilities and Shareholders' Equity	$	(2,181,987	)	$	930,359		$	535,381		$	—	$	2,096,725		$	(328,911	)	$	1,051,567

A condensed consolidating statement of operations of the Company for the six months ended June 30, 2025:

	Yubo International Biotech Limited (Parent Company)			Platinum (Cayman Island) and Platinum HK (Cayman Island)		Yubo Global			Yubo Chengdu (WFOE)		Yubo Beijing (VIE Subsidiaries)			Elimination		Consolidated
Sales of product and services	$	—		$	—	$	—		$	—	$	—		$	—	$	—
Cost of goods and services sold		—			—		—			—		—			—		—
Gross profit		—			—		—			—		—			—		—
Total operating expenses		—			—		—			—		592,094			—		592,094
Loss from operations		—			—		—			—		(592,094	)		—		(592,094	)
Other income (expense)		—			—		(2	)		—		(40	)		—		(42	)
Equity in net loss of subsidiaries and variable interest entity (VIE)		(1,628,906	)		—		—			—		—			1,628,906		—
Net Loss	$	(1,628,906	)	$	—	$	(2	)	$	—	$	(592,134	)	$	1,628,906	$	(592,136	)